D. Street

A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

M. D. del Carmen, Laurie Small, A. Londhe, 2012, Gynecologic oncology.

Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.

C. Pippitt, L. Asmar, C. L. Bailey, 2004, Gynecologic oncology.

A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.

B. Monk, C. Muller, M. Hensley, 2012, Gynecologic oncology.

Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study

R. Burger, D. Cella, P. Disaia, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interferon-γ Enhances Susceptibility of Cervical Cancer Cells to Lysis by Tumor-Specific Cytotoxic T Cells

S. Fisher, A. Vaughan, A. Kaufmann, 1997 .

Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells.

A. Vaughan, A. Kaufmann, L. Gissmann, 1997, Gynecologic oncology.

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.

P. Thaker, R. Coleman, W. Mcguire, 2015, Gynecologic oncology.

Regulation of human papillomavirus type 18 in vivo: effects of estrogen and progesterone in transgenic mice.

A. Kaufmann, L. Gissmann, R. Potkul, 1997, Gynecologic oncology.

Breast and cervical cancer

D. Street, A. Heath, L. Harris, 2010 .

Expression of CD80 enhances immunogenicity of cervical carcinoma cells in vitro.

A. Kaufmann, L. Gissmann, L. Qiao, 1996, Cellular immunology.

Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: Results of a phase II study.

M. D. del Carmen, A. Londhe, J. Micha, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.